Search Result

Results for "

phenotypic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Antibiotic (1) Apoptosis (2) Arf Family GTPase (1) ATP Synthase (1) Autophagy (1) Bacterial (1) Bcl-2 Family (1) Biochemical Assay Reagents (1) Caspase (1) CaSR (1) DGK (1) DYRK (1) Endogenous Metabolite (2) Environmental Pollutants (1) Farnesyl Transferase (1) HSP (2) Influenza Virus (1) IRAK (1) Kallikrein (1) Keap1-Nrf2 (1) mGluR (1) mTOR (1) NF-κB (2) NTPDase (1) PI3K (1) PKC (1) Potassium Channel (1) Pyroptosis (1) Pyruvate Kinase (1) Quinone Reductase (1) Ras (1) Reference Standards (2) SOD (1) Tau Protein (2) TNF Receptor (1) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (3) Endocrinology (1) Infection (5) Inflammation/Immunology (6) Metabolic Disease (1) Neurological Disease (5)

By Targets:

Akt (1)

Antibiotic (1)

Apoptosis (2)

Arf Family GTPase (1)

ATP Synthase (1)

Autophagy (1)

Bacterial (1)

Bcl-2 Family (1)

Biochemical Assay Reagents (1)

Caspase (1)

CaSR (1)

DGK (1)

DYRK (1)

Endogenous Metabolite (2)

Environmental Pollutants (1)

Farnesyl Transferase (1)

HSP (2)

Influenza Virus (1)

IRAK (1)

Kallikrein (1)

Keap1-Nrf2 (1)

mGluR (1)

mTOR (1)

NF-κB (2)

NTPDase (1)

PI3K (1)

PKC (1)

Potassium Channel (1)

Pyroptosis (1)

Pyruvate Kinase (1)

Quinone Reductase (1)

Ras (1)

Reference Standards (2)

SOD (1)

Tau Protein (2)

TNF Receptor (1)

Transmembrane Glycoprotein (1)

By Research Areas:

Cancer (9)

Cardiovascular Disease (3)

Endocrinology (1)

Infection (5)

Inflammation/Immunology (6)

Metabolic Disease (1)

Neurological Disease (5)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101026

CCT251236 4 Publications Verification	HSP	Cancer
CCT251236 is an orally available pirin ligand from a heat shock transcription factor 1 (hsf1) phenotypic screen with an IC₅₀ of 19 nM for inhibition of HSF1-mediated HSP72 induction.

HY-149874

BMS-502 1 Publications Verification	DGK	Inflammation/Immunology Cancer
BMS-502 (Compound 22) is a potent dual inhibitor of diacylglycerol kinase (DGK) α and ζ with IC₅₀ of 4.6 nM and 2.1 nM. BMS-502 enhanced T cell immune responses in mice. BMS-502 can be used in tumor immunity related research .

HY-P99236

Bexmarilimab 1 Publications Verification FP-1305	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Bexmarilimab (FP-1305) is a potent humanized anti-CLEVER-1 IgG4 antibody with an IC₅₀ value of 4.51 nM. Bexmarilimab is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab can promote antigen presentation and pro-inflammatory cytokine secretion. Bexmarilimab can induce B-cell and T-cell activation. Bexmarilimab can be used in researches of immunology and cancer, such as colorectal carcinoma .

HY-11095

NPS 2390	mGluR CaSR PI3K Akt mTOR Autophagy Apoptosis Bcl-2 Family Caspase	Cardiovascular Disease Neurological Disease
NPS 2390 is an allosteric antagonist of calcium-sensing receptor (CaSR) and mGluR1/5. NPS 2390 inhibits the PI3K/Akt/mTOR signaling pathway, reduces hypoxia-induced intracellular calcium elevation, decreases the expression of autophagy (autophagy) proteins, regulates the expression of phenotypic marker proteins, and inhibits the proliferation of pulmonary artery smooth muscle cells. NPS 2390 attenuates the endogenous apoptosis (apoptosis) pathway, increases the expression level of Bcl-2, downregulates the expression levels of Bax, cytochrome c and caspase-3, alleviates cerebral edema and improves neurological function in rat models. NPS 2390 can be used in studies related to hypoxic pulmonary hypertension, traumatic brain injury, stroke and pain .

HY-P991444

IPH5201	NTPDase ATP Synthase	Inflammation/Immunology Cancer
IPH5201 is a selective CD39 inhibitor and a humanized IgG1 monoclonal antibody. IPH5201 selectively binds to and inhibits the enzymatic activity of both membrane-bound and soluble CD39, blocking ATP hydrolysis. IPH5201 enhances the phenotypic maturation and activation of dendritic cells and macrophages. IPH5201 potentiates the anti-tumor effect of Oxaliplatin (HY-17371). IPH5201 shows preliminary evidence of disease stabilization in advanced solid tumor models when used as a single agent or in combination with Durvalumab (HY-P9919). IPH5201 can be used for the research of advanced solid tumors .

HY-W004570

5-Nitro-1,10-phenanthroline 5-NP	Endogenous Metabolite	Infection
5-Nitro-1,10-phenanthroline (5-NP), is a o-Phenanthroline (HY-W004544) derivative, as a mediator of glucose oxidase (GOX) with antituberculous activity. 5-Nitro-1,10-phenanthroline can be applied as redox mediators for oxidases and is suitable for the development of reagent-less biosensors and biofuel cells .

HY-175668

IDOR-1104-0086	Potassium Channel	Neurological Disease
IDOR-1104-0086 is an orally active K_v7 potassium channel opener with an EC₅₀ of 210 nM that can cross blood-brain barrier. IDOR-1104-0086 displays strong selectivity against the hERG channel with an IC₂₀ of 25 μM. IDOR-1104-0086 exhibits efficacy in two rodent models of epilepsy and a favorable tolerability profile. IDOR-1104-0086 can used for the study of epilepsy .

HY-N2439

Methyl isoeugenol	Environmental Pollutants Pyroptosis SOD Quinone Reductase Keap1-Nrf2 NF-κB	Cardiovascular Disease
Methyl isoeugenol is an orally active, blood-brain barrier-permeable isoeugenol-type eugenol analog. Methyl isoeugenol promotes the nuclear translocation of Nrf2, upregulates the expressions of HO-1, NQO1 and SOD, and reduces the expression level of MDA. Methyl isoeugenol decreases the nuclear translocation of NF-κB. Methyl isoeugenol inhibits NLRP3 inflammasome-mediated pyroptosis. Methyl isoeugenol reduces cerebral infarction volume and regulates the M1/M2 phenotypic balance of microglia. Methyl isoeugenol can be used for the research of cerebral ischemia-reperfusion injury .

HY-178012

GLPG4471	IRAK TNF Receptor	Inflammation/Immunology
GLPG4471 is a selective and orally active IRAK4 inhibitor with an IC₅₀ of 1.7 nM. GLPG4471 exhibits potent inhibition of cytokine (TNFα and IFNα) secretion in cellular and whole blood phenotypic assays. GLPG4471 displays significant activity in a mouse model of collagen-induced arthritis. GLPG4471 can be used for the study of arthritis .

HY-125153

Bursin	Influenza Virus	Others
Bursin is a peptide that can be isolated from the bursa of Fabricius of chicken. Bursin induces the phenotypic differentiation of mammalian and avian B precursor cells. Bursin also increases cyclic guanosine monophosphate in cells of the human B-cell line Daudi, its derivatives are able to protect against infection by amplifying the immune response induced by H9N2 .

HY-142655

Ftase inhibitor III	Farnesyl Transferase	Infection
Ftase inhibitor III is an anion-dependent Farnesyltransferase inhibitor from a phenotypic screen.

HY-122989

Aristolactam BIII	DYRK	Inflammation/Immunology
Aristolactam BIII is a potent DYRK1A inhibitor and inhibits the kinase activity of DYRK1A in vitro (IC₅₀= 9.67 nM. Aristolactam BIII rescues the proliferative defects of DYRK1A transgenic (TG) mouse-derived fibroblasts and neurological and phenotypic defects of DS-like Drosophila models .

HY-125153A

Bursin triacetate	Others	Endocrinology
Bursin triacetate is a peptide that can be isolated from the bursa of Fabricius in chickens. It promotes the phenotypic differentiation of B precursor cells in both mammals and birds. Bursin triacetate increases cyclic guanosine monophosphate levels in the human B-cell line Daudi .

HY-139863

Antibacterial agent 62	Bacterial	Infection
Antibacterial agent 62 is a novel redox cycling antituberculosis chemotype with potent bactericidal activity against growing and nutrient-starved phenotypically drug-resistant nongrowing bacteria.

HY-W048303

L-Azatyrosine	Antibiotic	Infection Cancer
L-Azatyrosine is an antitumor antibiotic isolated from Streptomyces chibaensis. L-Azatyrosine can restore normal phenotypic behavior to transformed cells bearing oncogenic Ras genes .

HY-116557

JCP-265	Biochemical Assay Reagents	Others
JCP-265 is a compound used for in vivo phenotypic screening of small molecule libraries, which has the activity of screening molecules that regulate cell function. JCP-265 uses molecular cell barcoding technology to directly screen small molecule libraries in vivo for studying complex physiological processes, such as screening compounds related to targets in pancreatic cancer metastasis seeding studies.

HY-176936

Tau-aggregation-IN-5	Tau Protein	Neurological Disease
Tau-aggregation-IN-5 is a Tau-aggregation inhibitor (EC₅₀ = 0.31 μM). Tau-aggregation-IN-5 targets P4HB covalently and activates mild ER stress. Tau-aggregation-IN-4 can be used for the study of neurodegenerative disorders such as Alzheimer’s and Pick’s diseases .

HY-176238

CX116	Apoptosis	Metabolic Disease Cancer
CX116 is an orally active anti-inflammatory agent. CX116 exerts its effects by inhibiting the inflammatory response, reducing oxidative stress, protecting mitochondrial function, and counteracting apoptosis. CX116 bears acceptable toxicity, and can significantly protect renal tissue from Cisplatin (HY-17394)-induced damage. CX116 can be used for the study of Cisplatin-induced acute kidney injury (cis-AKI) .

HY-178927

Tau-aggregation-IN-4	Tau Protein	Neurological Disease
Tau-aggregation-IN-4 is a Tau-aggregation inhibitor (EC₅₀ = 2.99 μM). Tau-aggregation-IN-4 can be used for the study of neurodegenerative disorders such as Alzheimer’s and Pick’s diseases .

HY-175290

Arf1-GEFs-IN-1	Arf Family GTPase	Cancer
Arf1-GEFs-IN-1 is a potent and orally active ADP-ribosylation factor 1- guanine nucleotide exchange factors (Arf1-GEFs) inhibitor with an IC₅₀ value of 40.85 μM against CT26 cells. Arf1-GEFs-IN-1 primarily mediates tumor regression by triggering anti-tumor immune responses, rather than through direct cytotoxicity. Arf1-GEFs-IN-1 effectively promotes CCL5 expression, demonstrates excellent in vivo efficacy. Arf1-GEFs-IN-1 can be used for the study of colon cancer .

HY-101026R

CCT251236 (Standard)	HSP Reference Standards	Cancer
CCT251236 (Standard) is the analytical standard of CCT251236 (HY-101026). This product is intended for research and analytical applications. CCT251236 is an orally available pirin ligand from a heat shock transcription factor 1 (hsf1) phenotypic screen with an IC50 of 19 nM for inhibition of HSF1-mediated HSP72 induction.

HY-180796

PKM2 agonist-1	Pyruvate Kinase	Cardiovascular Disease
PKM2 agonist-1 (Compound D16) is a highly effective, allosteric PKM2 agonist with an AC₅₀ value of 77 nM. PKM2 agonist-1 inhibits Ang II-induced smooth muscle cell phenotypic switching. PKM2 agonist-1 effectively prevents aortic dissection and results in reduced mortality .

HY-180779

SR-1815	Ras	Neurological Disease
SR-1815 is a small molecule multi-kinase inhibitor. SR-1815, through mechanisms such as splicing regulation effectively restores the SynGAP protein to normal levels in the disease model with Syngap1 haploinsufficiency, thereby correcting the functional abnormalities at the synaptic and neuronal network levels caused by the deficiency of this gene. SR-1815 can be used for the study of brain diseases .

HY-124714

DKFZ-251	Kallikrein	Cancer
DKFZ-251 is a kininogenase-related peptidase KLK6 inhibitor (IC₅₀=0.47 μM), and also exhibits certain inhibitory activity against KLK5 and KLK7 (IC₅₀ values are 1.1 nM and 73 nM, respectively). DKFZ-251 transiently acylates the catalytic serine of KLK6 to form a long-lived acyl-enzyme complex that inhibits enzyme function. DKFZ-251 is a phenotypic modulator that alters cell proliferation capacity and regulates epithelial-mesenchymal transition (EMT). DKFZ-251 can be used in research related to head and neck cancer .

HY-W004570R

5-Nitro-1,10-phenanthroline (Standard) 5-NP (Standard)	Endogenous Metabolite Reference Standards	Infection
5-Nitro-1,10-phenanthroline (Standard) (5-NP (Standard)) is the analytical standard of 5-Nitro-1,10-phenanthroline (HY-W004570). This product is intended for research and analytical applications. 5-Nitro-1,10-phenanthroline (5-NP), is a o-Phenanthroline (HY-W004544) derivative, as a mediator of glucose oxidase (GOX) with antituberculous activity. 5-Nitro-1,10-phenanthroline can be applied as redox mediators for oxidases and is suitable for the development of reagent-less biosensors and biofuel cells .

HY-10540

Sotrastaurin acetate AEB071 acetate	PKC NF-κB	Inflammation/Immunology
Sotrastaurin (AEB071) acetate is a selective, orally active PKC inhibitor. Sotrastaurin acetate inactivates NF-κB by inhibiting PKC α, β, θ, γ subtypes, thereby reducing the transcription levels of immune response-related genes. Sotrastaurin acetate effectively inhibits alloreactive T cell proliferation, conventional T cell activation, as well as the production of pro-inflammatory cytokines and B lymphocytes. Sotrastaurin acetate also maintains the functional and phenotypic stability of regulatory T cells, enhances Foxp3 expression and restores the balance of helper T lymphocytes. Sotrastaurin acetate can prolong the survival time of allografts, and alleviate inflammatory responses and myasthenic symptoms by reducing anti-AChR antibody levels. Sotrastaurin acetate is widely used in studies related to kidney transplantation, psoriasis and myasthenia gravis .

Cat. No.	Product Name

HY-L099

Targeted Diversity Library	2,300 compounds
MCE Targeted Diversity Library contains 2,300 compounds, covering more than 1000 targets and isoforms, such as GPCRs, Ion channel, variety of kinases, etc. 1-3 compounds with high potency and selectivity were carefully selected for each target and isoform. The bioactivity information of each compound has been clearly reported in the literatures. This library is a concise collection of small molecule compounds with comprehensive target coverage, which can be used for phenotypic screening at low cost.

Targeted Diversity Library

2,300 compounds

MCE Targeted Diversity Library contains 2,300 compounds, covering more than 1000 targets and isoforms, such as GPCRs, Ion channel, variety of kinases, etc. 1-3 compounds with high potency and selectivity were carefully selected for each target and isoform. The bioactivity information of each compound has been clearly reported in the literatures. This library is a concise collection of small molecule compounds with comprehensive target coverage, which can be used for phenotypic screening at low cost.

HY-L005M

Epigenetics Compound Library Mini	297 compounds
Epigenetics involves heritable phenotypic changes that occur without alterations to the underlying DNA sequence. Key mechanisms include DNA methylation, histone modifications, and regulation by small non-coding RNAs such as microRNAs. By modifying DNA, histones, or RNA—while leaving their primary sequences intact—these processes influence molecular function and regulation, thereby playing critical roles in cellular differentiation, embryonic development, gene expression control, aging, and diseases such as cancer. MCE provide a unique collection of 297 epigenetics-related compounds. For each regulatory target and its subtype, 3 to 5 highly specific representative compounds have been retained, which can be used in epigenetic and related disease research.

Epigenetics Compound Library Mini

297 compounds

Epigenetics involves heritable phenotypic changes that occur without alterations to the underlying DNA sequence. Key mechanisms include DNA methylation, histone modifications, and regulation by small non-coding RNAs such as microRNAs. By modifying DNA, histones, or RNA—while leaving their primary sequences intact—these processes influence molecular function and regulation, thereby playing critical roles in cellular differentiation, embryonic development, gene expression control, aging, and diseases such as cancer.

MCE provide a unique collection of 297 epigenetics-related compounds. For each regulatory target and its subtype, 3 to 5 highly specific representative compounds have been retained, which can be used in epigenetic and related disease research.

HY-L207

Mass Spectrometry Human Endogenous Metabolite Library	664 compounds
Metabolomics is the large-scale study of cellular metabolic complement, with proven utility in both basic and applied studies of plants, microorganisms, and mammals. As an important tool for the study of complex biological systems, metabolomics monitors the complex molecular networks that exist in the natural flow of information from genes to mRNA and proteins to organisms. The metabolome is composed of biomolecules that most closely resemble the phenotype of an organism, and changes in its composition can easily lead to the production of diseases. Therefore, metabolomics has received much attention in drug target discovery, drug response and translational research of disease mechanisms. Mass spectrometry-based metabolomics methods can simultaneously detect and quantify thousands of metabolite signatures, thereby characterizing the pathophysiological mechanisms of various biomedical symptoms. MCE can provide 664 mass spectrometry human endogenous metabolites that can be used for metabolite identification and quantification, functional cell detection and phenotypic screening of mass spectrometry.

Mass Spectrometry Human Endogenous Metabolite Library

664 compounds

Metabolomics is the large-scale study of cellular metabolic complement, with proven utility in both basic and applied studies of plants, microorganisms, and mammals. As an important tool for the study of complex biological systems, metabolomics monitors the complex molecular networks that exist in the natural flow of information from genes to mRNA and proteins to organisms. The metabolome is composed of biomolecules that most closely resemble the phenotype of an organism, and changes in its composition can easily lead to the production of diseases. Therefore, metabolomics has received much attention in drug target discovery, drug response and translational research of disease mechanisms. Mass spectrometry-based metabolomics methods can simultaneously detect and quantify thousands of metabolite signatures, thereby characterizing the pathophysiological mechanisms of various biomedical symptoms.

MCE can provide 664 mass spectrometry human endogenous metabolites that can be used for metabolite identification and quantification, functional cell detection and phenotypic screening of mass spectrometry.

HY-L215

Mass Spectrometry Human Metabolite Library	5,923 compounds
Metabolomics, positioned as the systemic characterization of small-molecule metabolites within biological systems, has emerged as an indispensable analytical platform in both fundamental research and translational applications across plant sciences, microbial biotechnology, and biomedical investigations. Functioning as a critical component in multi-omics integration, this discipline deciphers the intricate molecular networks operating downstream of genomic, transcriptomic, and proteomic regulation, thereby capturing the dynamic biochemical phenotype closest to organismal functionality. The metabolome, comprising endogenous compounds with molecular weights typically below 1500 Da, serves as the functional readout of cellular processes and environmental interactions, where perturbations in metabolic networks are frequently implicated in disease pathogenesis. Such unique attributes have propelled metabolomics into a pivotal role in pharmacological research, particularly in target deconvolution, pharmacodynamic assessment, and mechanistic elucidation of pathological processes. MCE can provide 5,923 mass spectrometry human metabolites that can be used for metabolite identification and quantification, functional cell detection and phenotypic screening of mass spectrometry.

Mass Spectrometry Human Metabolite Library

5,923 compounds

Metabolomics, positioned as the systemic characterization of small-molecule metabolites within biological systems, has emerged as an indispensable analytical platform in both fundamental research and translational applications across plant sciences, microbial biotechnology, and biomedical investigations. Functioning as a critical component in multi-omics integration, this discipline deciphers the intricate molecular networks operating downstream of genomic, transcriptomic, and proteomic regulation, thereby capturing the dynamic biochemical phenotype closest to organismal functionality. The metabolome, comprising endogenous compounds with molecular weights typically below 1500 Da, serves as the functional readout of cellular processes and environmental interactions, where perturbations in metabolic networks are frequently implicated in disease pathogenesis. Such unique attributes have propelled metabolomics into a pivotal role in pharmacological research, particularly in target deconvolution, pharmacodynamic assessment, and mechanistic elucidation of pathological processes.

MCE can provide 5,923 mass spectrometry human metabolites that can be used for metabolite identification and quantification, functional cell detection and phenotypic screening of mass spectrometry.

HY-L034M

Anti-Aging Compound Library Mini	381 compounds
Research has shown that drugs targeting aging pathways demonstrate promising potential in models of age-related diseases such as Alzheimer's disease, cardiovascular diseases, metabolic syndrome, osteoarthritis, and various malignancies. This suggests that intervening in the biological processes of aging may enable synergistic prevention and treatment of multiple chronic diseases. Against the backdrop of the gradual elucidation of core aging mechanisms-including cellular senescence, telomere attrition, epigenetic dysregulation, and chronic inflammation anti-aging research has shifted from traditional phenotypic interventions toward targeting key pathways that regulate biological age. The MCE Anti-Aging Compound Library Mini is precisely built upon this cutting-edge concept. It focuses on aging-related targets validated through genetic or functional studies, comprising 381 compounds designed to provide systematic research tools for aging biology and intervention strategy development. The library covers core mechanisms such as mTOR, SIRT, energy metabolism, clearance of senescent cells, optimization of mitochondrial function, and telomere maintenance. For each target, 1-5 compounds with clear activity and strong representativeness have been carefully selected, spanning the entire translational spectrum from preclinical tool molecules to clinically investigational drugs.

Anti-Aging Compound Library Mini

381 compounds

Research has shown that drugs targeting aging pathways demonstrate promising potential in models of age-related diseases such as Alzheimer's disease, cardiovascular diseases, metabolic syndrome, osteoarthritis, and various malignancies. This suggests that intervening in the biological processes of aging may enable synergistic prevention and treatment of multiple chronic diseases. Against the backdrop of the gradual elucidation of core aging mechanisms-including cellular senescence, telomere attrition, epigenetic dysregulation, and chronic inflammation anti-aging research has shifted from traditional phenotypic interventions toward targeting key pathways that regulate biological age.

The MCE Anti-Aging Compound Library Mini is precisely built upon this cutting-edge concept. It focuses on aging-related targets validated through genetic or functional studies, comprising 381 compounds designed to provide systematic research tools for aging biology and intervention strategy development. The library covers core mechanisms such as mTOR, SIRT, energy metabolism, clearance of senescent cells, optimization of mitochondrial function, and telomere maintenance. For each target, 1-5 compounds with clear activity and strong representativeness have been carefully selected, spanning the entire translational spectrum from preclinical tool molecules to clinically investigational drugs.

HY-L248

RNA Binding Bioactive Compound Library	857 compounds
The RNA-targeted bioactive compound library is a high-quality collection of small molecules specifically designed and curated to target RNA structures and functions. It is widely applied in cutting-edge drug discovery and life science research. Unlike traditional strategies that focus on protein targets, RNA-targeted compounds can directly modulate various functional RNA molecules by influencing their splicing, translation, stability, or structural conformation, thereby enabling precise intervention in key biological processes. In the field of drug development, these compounds provide a novel approach to addressing previously “undruggable” targets and have demonstrated significant potential in areas such as oncology, antiviral therapies, and neurodegenerative diseases. For example, by targeting disease-associated RNA structural domains or regulating the aberrant expression of non-coding RNAs, these compounds can effectively inhibit disease progression or restore normal cellular function. In mechanistic studies, RNA-targeted compounds serve as valuable chemical biology tools to elucidate the roles of RNA in gene expression regulation, cellular signaling pathways, and disease development. The MCE RNA-targeted bioactive compound library contains 857 compounds, sourced from databases such as TargetRX Atlas and R-BIND. The library features excellent structural diversity and biological activity, making it suitable for high-throughput screening (HTS), target validation, phenotypic screening, and lead compound discovery. It represents a valuable resource for RNA-related research and innovative drug development.

RNA Binding Bioactive Compound Library

857 compounds

The RNA-targeted bioactive compound library is a high-quality collection of small molecules specifically designed and curated to target RNA structures and functions. It is widely applied in cutting-edge drug discovery and life science research. Unlike traditional strategies that focus on protein targets, RNA-targeted compounds can directly modulate various functional RNA molecules by influencing their splicing, translation, stability, or structural conformation, thereby enabling precise intervention in key biological processes. In the field of drug development, these compounds provide a novel approach to addressing previously “undruggable” targets and have demonstrated significant potential in areas such as oncology, antiviral therapies, and neurodegenerative diseases. For example, by targeting disease-associated RNA structural domains or regulating the aberrant expression of non-coding RNAs, these compounds can effectively inhibit disease progression or restore normal cellular function. In mechanistic studies, RNA-targeted compounds serve as valuable chemical biology tools to elucidate the roles of RNA in gene expression regulation, cellular signaling pathways, and disease development.

The MCE RNA-targeted bioactive compound library contains 857 compounds, sourced from databases such as TargetRX Atlas and R-BIND. The library features excellent structural diversity and biological activity, making it suitable for high-throughput screening (HTS), target validation, phenotypic screening, and lead compound discovery. It represents a valuable resource for RNA-related research and innovative drug development.

Cat. No.	Product Name	Target	Research Area